Juergen Siepmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1944339/publications.pdf

Version: 2024-02-01

212	16,051	22153	18130
papers	citations	59 h-index	120 g-index

215	215	215	13410
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 2001, 48, 139-157.	13.7	1,882
2	Mathematical modeling of drug delivery. International Journal of Pharmaceutics, 2008, 364, 328-343.	5.2	1,036
3	Higuchi equation: Derivation, applications, use and misuse. International Journal of Pharmaceutics, 2011, 418, 6-12.	5.2	719
4	Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 2012, 64, 163-174.	13.7	661
5	Mathematical modeling of bioerodible, polymeric drug delivery systems. Advanced Drug Delivery Reviews, 2001, 48, 229-247.	13.7	651
6	Modeling of diffusion controlled drug delivery. Journal of Controlled Release, 2012, 161, 351-362.	9.9	641
7	Mathematical modeling of drug dissolution. International Journal of Pharmaceutics, 2013, 453, 12-24.	5.2	338
8	PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. European Journal of Pharmaceutical Sciences, 2002, 15, 355-366.	4.0	297
9	HPMC-matrices for controlled drug delivery: a new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharmaceutical Research, 1999, 16, 1748-1756.	3.5	288
10	How porosity and size affect the drug release mechanisms from PLGA-based microparticles. International Journal of Pharmaceutics, 2006, 314, 198-206.	5.2	287
11	Polymer blends for controlled release coatings. Journal of Controlled Release, 2008, 125, 1-15.	9.9	267
12	How Autocatalysis Accelerates Drug Release from PLGA-Based Microparticles:Â A Quantitative Treatment. Biomacromolecules, 2005, 6, 2312-2319.	5.4	257
13	Effect of the size of biodegradable microparticles on drug release: experiment and theory. Journal of Controlled Release, 2004, 96, 123-134.	9.9	234
14	PLGA-based drug delivery systems: Importance of the type of drug and device geometry. International Journal of Pharmaceutics, 2008, 354, 95-103.	5.2	215
15	Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery, 2006, 3, 217-233.	5.0	212
16	Drug delivery to the upper small intestine window using gastroretentive technologies. Current Opinion in Pharmacology, 2006, 6, 501-508.	3.5	193
17	Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the "sequential layer" model). Pharmaceutical Research, 2000, 17, 1290-1298.	3.5	189
18	Effect of the size of biodegradable microparticles on drug release: experiment and theory. Journal of Controlled Release, 2004, 96, 123-123.	9.9	161

#	Article	IF	Citations
19	Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. European Journal of Pharmaceutical Sciences, 2003, 18, 37-45.	4.0	158
20	pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets. Journal of Controlled Release, 2000, 67, 101-110.	9.9	154
21	A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets. Journal of Pharmaceutical Sciences, 1999, 88, 65-72.	3.3	153
22	Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles. Journal of Controlled Release, 1999, 60, 379-389.	9.9	146
23	A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations. Pharmaceutical Research, 2002, 19, 1885-1893.	3.5	146
24	Effects of the type of release medium on drug release from PLGA-based microparticles: Experiment and theory. International Journal of Pharmaceutics, 2006, 314, 189-197.	5.2	141
25	Floating microparticles based on low density foam powder. International Journal of Pharmaceutics, 2002, 241, 279-292.	5.2	135
26	Calculation of the required size and shape of hydroxypropyl methylcellulose matrices to achieve desired drug release profiles. International Journal of Pharmaceutics, 2000, 201, 151-164.	5.2	125
27	Understanding and predicting drug delivery from hydrophilic matrix tablets using the "sequential layer" model. Pharmaceutical Research, 2002, 19, 306-314.	3.5	123
28	Blends of enteric and GIT-insoluble polymers used for film coating: physicochemical characterization and drug release patterns. Journal of Controlled Release, 2003, 89, 457-471.	9.9	120
29	Recombinant gelatin hydrogels for the sustained release of proteins. Journal of Controlled Release, 2007, 119, 301-312.	9.9	112
30	Polymer Blends Used for the Coating of Multiparticulates: Comparison of Aqueous and Organic Coating Techniques. Pharmaceutical Research, 2004, 21, 882-890.	3.5	107
31	Polymer blends used for the aqueous coating of solid dosage forms: importance of the type of plasticizer. Journal of Controlled Release, 2004, 99, 1-13.	9.9	105
32	Lipids and polymers in pharmaceutical technology: Lifelong companions. International Journal of Pharmaceutics, 2019, 558, 128-142.	5.2	101
33	Pharmaceutical Applications of Shellac: Moisture-Protective and Taste-Masking Coatings and Extended-Release Matrix Tablets. Drug Development and Industrial Pharmacy, 2003, 29, 925-938.	2.0	98
34	Sustained release of nanosized complexes of polyethylenimine and anti-TGF-Î²2 oligonucleotide improves the outcome of glaucoma surgery. Journal of Controlled Release, 2006, 112, 369-381.	9.9	93
35	How to adjust desired drug release patterns from ethylcellulose-coated dosage forms. Journal of Controlled Release, 2007, 119, 182-189.	9.9	93
36	Bimodal drug release achieved with multi-layer matrix tablets: transport mechanisms and device design. Journal of Controlled Release, 2000, 69, 455-468.	9.9	89

#	Article	IF	Citations
37	Drugs acting as plasticizers in polymeric systems: A quantitative treatment. Journal of Controlled Release, 2006, 115, 298-306.	9.9	87
38	Mathematical modeling of controlled drug delivery. Advanced Drug Delivery Reviews, 2001, 48, 137-138.	13.7	80
39	Does PLGA microparticle swelling control drug release? New insight based on single particle swelling studies. Journal of Controlled Release, 2015, 213, 120-127.	9.9	80
40	Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 271-279.	4.3	78
41	Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: Preparation and physicochemical characterization. International Journal of Pharmaceutics, 2006, 314, 127-136.	5.2	77
42	Key parameters affecting the initial release (burst) and encapsulation efficiency of peptide-containing poly(lactide-co-glycolide) microparticles. International Journal of Pharmaceutics, 2006, 324, 168-175.	5.2	77
43	Prediction of drug release from ethylcellulose coated pellets. Journal of Controlled Release, 2009, 135, 71-79.	9.9	77
44	Often neglected: PLGA/PLA swelling orchestrates drug release: HME implants. Journal of Controlled Release, 2019, 306, 97-107.	9.9	77
45	Local controlled drug delivery to the brain: Mathematical modeling of the underlying mass transport mechanisms. International Journal of Pharmaceutics, 2006, 314, 101-119.	5.2	76
46	Alginateâ€“poloxamer microparticles for controlled drug delivery to mucosal tissue. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 42-53.	4.3	74
47	Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. Journal of Controlled Release, 2003, 88, 413-428.	9.9	73
48	Influence of urea and guanidine hydrochloride on lysozyme stability and thermal denaturation; a correlation between activity, protein dynamics and conformational changes. Physical Chemistry Chemical Physics, 2010, 12, 13189.	2.8	73
49	pH-Sensitive Polymer Blends Used as Coating Materials to Control Drug Release from Spherical Beads: Elucidation of the Underlying Mass Transport Mechanisms. Pharmaceutical Research, 2005, 22, 1129-1141.	3.5	72
50	Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasone-loaded systems. International Journal of Pharmaceutics, 2016, 514, 189-199.	5.2	71
51	Multiple unit gastroretentive drug delivery systems: A new preparation method for low density microparticles. Journal of Microencapsulation, 2003, 20, 329-347.	2.8	70
52	Mobility of model proteins in hydrogels composed of oppositely charged dextran microspheres studied by protein release and fluorescence recovery after photobleaching. Journal of Controlled Release, 2005, 110, 67-78.	9.9	70
53	Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 68-83.	6.4	69
54	Calculation of the Dimensions of Drug-Polymer Devices Based on Diffusion Parameters. Journal of Pharmaceutical Sciences, 1998, 87, 827-832.	3.3	67

#	Article	IF	Citations
55	Drug release from lipid-based implants: Elucidation of the underlying mass transport mechanisms. International Journal of Pharmaceutics, 2006, 314, 137-144.	5.2	66
56	Drug release from PLGA-based microparticles: Effects of the â€œmicroparticle:bulk fluidâ€•ratio. International Journal of Pharmaceutics, 2010, 383, 123-131.	5.2	66
57	Mathematical modeling of drug release from lipid dosage forms. International Journal of Pharmaceutics, 2011, 418, 42-53.	5.2	64
58	Mechanisms controlling protein release from lipidic implants: Effects of PEG addition. Journal of Controlled Release, 2007, 118, 161-168.	9.9	63
59	Blends of aqueous polymer dispersions used for pellet coating: Importance of the particle size. Journal of Controlled Release, 2005, 105, 226-239.	9.9	61
60	Curing of aqueous polymeric film coatings: Importance of the coating level and type of plasticizer. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 362-370.	4.3	60
61	In situ forming implants for periodontitis treatment with improved adhesive properties. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 342-350.	4.3	60
62	Modeling drug release from PVAc/PVP matrix tablets. Journal of Controlled Release, 2010, 141, 216-222.	9.9	59
63	Development of injection moulded matrix tablets based on mixtures of ethylcellulose and low-substituted hydroxypropylcellulose. European Journal of Pharmaceutical Sciences, 2009, 37, 207-216.	4.0	58
64	Development and evaluation of sustained-release clonidine-loaded PLGA microparticles. International Journal of Pharmaceutics, 2012, 437, 20-28.	5.2	58
65	How Strongly Does Trehalose Interact with Lysozyme in the Solid State? Insights from Molecular Dynamics Simulation and Inelastic Neutron Scattering. Journal of Physical Chemistry B, 2012, 116, 11103-11116.	2.6	58
66	Bone implants modified with cyclodextrin: Study of drug release in bulk fluid and into agarose gel. International Journal of Pharmaceutics, 2010, 400, 74-85.	5.2	57
67	Novel polymeric film coatings for colon targeting: Drug release from coated pellets. European Journal of Pharmaceutical Sciences, 2009, 37, 427-433.	4.0	56
68	Drug release mechanisms from ethylcellulose: PVA-PEG graft copolymer-coated pellets. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 130-137.	4.3	55
69	Effects of film coating thickness and drug layer uniformity on in vitro drug release from sustained-release coated pellets: A case study using terahertz pulsed imaging. International Journal of Pharmaceutics, 2009, 382, 151-159.	5.2	53
70	In-situ forming PLGA implants for intraocular dexamethasone delivery. International Journal of Pharmaceutics, 2018, 548, 337-348.	5.2	52
71	Cross-linking of chitosan and chitosan/poly(ethylene oxide) beads: A theoretical treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 339-348.	4.3	51
72	Clinical translation of advanced colonic drug delivery technologies. Advanced Drug Delivery Reviews, 2022, 181, 114076.	13.7	51

#	Article	IF	Citations
73	Microparticles Used as Drug Delivery Systems. , 2006, , 15-21.		48
74	Zincâ€“alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 121-130.	4.3	48
75	Novel preparation techniques for alginateâ€“poloxamer microparticles controlling protein release on mucosal surfaces. European Journal of Pharmaceutical Sciences, 2012, 45, 358-366.	4.0	48
76	Dexamethasone eluting electrodes for cochlear implantation: Effect on residual hearing. Cochlear Implants International, 2015, 16, 195-200.	1.2	48
77	How to improve the storage stability of aqueous polymeric film coatings. Journal of Controlled Release, 2008, 126, 26-33.	9.9	46
78	Drug release from MCC- and carrageenan-based pellets: Experiment and theory. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 302-309.	4.3	46
79	The effect of gamma-irradiation on drug release from bioerodible microparticles: a quantitative treatment. International Journal of Pharmaceutics, 2002, 242, 281-284.	5.2	45
80	Controlled drug release from Gelucire-based matrix pellets: Experiment and theory. International Journal of Pharmaceutics, 2006, 317, 136-143.	5.2	44
81	Methyl-Î²-cyclodextrin modified vascular prosthesis: Influence of the modification level on the drug delivery properties in different media. Acta Biomaterialia, 2011, 7, 304-314.	8.3	43
82	Predictability of drug release from cochlear implants. Journal of Controlled Release, 2012, 159, 60-68.	9.9	43
83	Comparative study of vascular prostheses coated with polycyclodextrins for controlled ciprofloxacin release. Carbohydrate Polymers, 2012, 90, 1695-1703.	10.2	41
84	Application of terahertz pulsed imaging to analyse film coating characteristics of sustained-release coated pellets. International Journal of Pharmaceutics, 2013, 457, 521-526.	5.2	41
85	pH-Sensitive Polymer Blends used as Coating Materials to Control Drug Release from Spherical Beads:Â Importance of the Type of Core. Biomacromolecules, 2005, 6, 2074-2083.	5.4	40
86	Drug release mechanisms of compressed lipid implants. International Journal of Pharmaceutics, 2011, 404, 27-35.	5.2	40
87	Towards More Realistic In Vitro Release Measurement Techniques for Biodegradable Microparticles. Pharmaceutical Research, 2009, 26, 691-699.	3.5	39
88	Aqueous HPMCAS coatings: Effects of formulation and processing parameters on drug release and mass transport mechanisms. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 63, 262-269.	4.3	38
89	Drug release mechanisms from Kollicoat SR:Eudragit NE coated pellets. International Journal of Pharmaceutics, 2011, 409, 30-37.	5.2	38
90	Sustained release from hot-melt extruded matrices based on ethylene vinyl acetate and polyethylene oxide. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 526-533.	4.3	38

#	Article	IF	Citations
91	PLGA implants: How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release. Journal of Controlled Release, 2017, 253, 19-29.	9.9	38
92	Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles. International Journal of Pharmaceutics, 2011, 404, 75-82.	5.2	37
93	Chitosan-clay nanocomposite microparticles for controlled drug delivery: Effects of the MAS content and TPP crosslinking. Journal of Drug Delivery Science and Technology, 2017, 40, 1-10.	3.0	37
94	Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. Journal of Microencapsulation, 2003, 20, 329-347.	2.8	37
95	New Insight into the Role of Polyethylene Glycol Acting as Protein Release Modifier in Lipidic Implants. Pharmaceutical Research, 2007, 24, 1527-1537.	3.5	35
96	Characterization of Moistureâ€Protective Polymer Coatings Using Differential Scanning Calorimetry and Dynamic Vapor Sorption. Journal of Pharmaceutical Sciences, 2009, 98, 651-664.	3.3	35
97	Stability of aqueous polymeric controlled release film coatings. International Journal of Pharmaceutics, 2013, 457, 437-445.	5.2	35
98	Ethanol-resistant polymeric film coatings for controlled drug delivery. Journal of Controlled Release, 2013, 169, 1-9.	9.9	35
99	In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance. International Journal of Pharmaceutics, 2015, 486, 38-51.	5.2	35
100	Importance of PLGA microparticle swelling for the control of prilocaine release. Journal of Drug Delivery Science and Technology, 2015, 30, 123-132.	3.0	35
101	Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug. International Journal of Pharmaceutics, 2011, 409, 289-296.	5.2	34
102	Mechanistic analysis of PLGA/HPMC-based in-situ forming implants for periodontitis treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 273-283.	4.3	34
103	In vivo efficacy of microbiota-sensitive coatings for colon targeting: A promising tool for IBD therapy. Journal of Controlled Release, 2015, 197, 121-130.	9.9	34
104	Sink conditions do not guarantee the absence of saturation effects. International Journal of Pharmaceutics, 2020, 577, 119009.	5.2	34
105	Lipid implants as drug delivery systems. Expert Opinion on Drug Delivery, 2008, 5, 291-307.	5.0	33
106	Modeling plasticizer uptake in aqueous polymer dispersions. International Journal of Pharmaceutics, 1998, 165, 191-200.	5.2	32
107	A novel mathematical model quantifying drug release from lipid implants. Journal of Controlled Release, 2008, 128, 233-240.	9.9	32
108	Protection of moisture-sensitive drugs with aqueous polymer coatings: Importance of coating and curing conditions. International Journal of Pharmaceutics, 2009, 378, 59-65.	5.2	32

#	Article	IF	Citations
109	Using Milling To Explore Physical States: The Amorphous and Polymorphic Forms of Dexamethasone. Crystal Growth and Design, 2018, 18, 1748-1757.	3.0	32
110	Colon targeting with bacteria-sensitive films adapted to the disease state. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 74-81.	4.3	31
111	Drug release mechanisms of cast lipid implants. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 394-400.	4.3	31
112	PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine. International Journal of Pharmaceutics, 2013, 443, 68-79.	5.2	31
113	Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair. Trends in Molecular Medicine, 2021, 27, 231-247.	6.7	31
114	Deeper insight into the drug release mechanisms in Eudragit RL-based delivery systems. International Journal of Pharmaceutics, 2010, 389, 139-146.	5.2	30
115	In vitro release studies of insulin from lipid implants in solution and in a hydrogel matrix mimicking the subcutis. European Journal of Pharmaceutical Sciences, 2016, 81, 103-112.	4.0	30
116	pH-sensitive film coatings: Towards a better understanding and facilitated optimization. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 2-10.	4.3	29
117	Improved long term stability of aqueous ethylcellulose film coatings: Importance of the type of drug and starter core. International Journal of Pharmaceutics, 2009, 368, 138-145.	5.2	29
118	Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration. Drug Development and Industrial Pharmacy, 2015, 41, 2037-2044.	2.0	29
119	MALDI-TOF MS imaging of controlled release implants. Journal of Controlled Release, 2012, 161, 98-108.	9.9	27
120	Gentamicin-loaded poly(lactic-co-glycolic acid) microparticles for the prevention of maxillofacial and orthopedic implant infections. Materials Science and Engineering C, 2016, 64, 108-116.	7.3	27
121	Predicting drug release from HPMC/lactose tablets. International Journal of Pharmaceutics, 2013, 441, 826-834.	5.2	26
122	Characterization and optimization of GMO-based gels with long term release for intraarticular administration. International Journal of Pharmaceutics, 2013, 451, 95-103.	5.2	26
123	Physical key properties of antibiotic-free, PLGA/HPMC-based in-situ forming implants for local periodontitis treatment. International Journal of Pharmaceutics, 2017, 521, 282-293.	5.2	26
124	Novel polymeric film coatings for colon targeting: How to adjust desired membrane properties. International Journal of Pharmaceutics, 2009, 371, 64-70.	5.2	25
125	Cubic phase-forming dry powders for controlled drug delivery on mucosal surfaces. Journal of Controlled Release, 2012, 157, 206-215.	9.9	25
126	Trans-Oval-Window Implants, A New Approach for Drug Delivery to the Inner Ear. Otology and Neurotology, 2015, 36, 1572-1579.	1.3	25

#	Article	IF	Citations
127	In-situ forming implants loaded with chlorhexidine and ibuprofen for periodontal treatment: Proof of concept study in vivo. International Journal of Pharmaceutics, 2019, 569, 118564.	5.2	25
128	GnRH neurons recruit astrocytes in infancy to facilitate network integration and sexual maturation. Nature Neuroscience, 2021, 24, 1660-1672.	14.8	25
129	Dynamic and static curing of ethylcellulose:PVAâ€“PEG graft copolymer film coatings. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 455-461.	4.3	24
130	Controlled release implants based on cast lipid blends. European Journal of Pharmaceutical Sciences, 2011, 43, 78-83.	4.0	24
131	PEO hot melt extrudates for controlled drug delivery: Importance of the molecular weight. Journal of Drug Delivery Science and Technology, 2016, 36, 130-140.	3.0	24
132	Programmable implantsâ€”From pulsatile to controlled release. International Journal of Pharmaceutics, 2006, 314, 161-169.	5.2	23
133	Characterisation of quaternary polymethacrylate films containing tartaric acid, metoprolol free base or metoprolol tartrate. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 366-372.	4.3	23
134	In vitro and in vivo behavior of ground tadalafil hot-melt extrudates: How the carrier material can effectively assure rapid or controlled drug release. International Journal of Pharmaceutics, 2017, 528, 498-510.	5.2	23
135	Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Diprophylline dispersions. International Journal of Pharmaceutics, 2019, 572, 118819.	5.2	23
136	Limited drug solubility can be decisive even for freely soluble drugs in highly swollen matrix tablets. International Journal of Pharmaceutics, 2017, 526, 280-290.	5.2	22
137	Ear Cubes for local controlled drug delivery to the inner ear. International Journal of Pharmaceutics, 2016, 509, 85-94.	5.2	21
138	Modeling drug release from hot-melt extruded mini-matrices with constant and non-constant diffusivities. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 292-301.	4.3	20
139	How to easily provide zero order release of freely soluble drugs from coated pellets. International Journal of Pharmaceutics, 2015, 478, 31-38.	5.2	20
140	Porous pellets as drug delivery system. Drug Development and Industrial Pharmacy, 2009, 35, 655-662.	2.0	18
141	Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. Journal of Pharmacy and Pharmacology, 2010, 62, 1676-1684.	2.4	18
142	Peas starchâ€based film coatings for siteâ€specific drug delivery to the colon. Journal of Applied Polymer Science, 2011, 119, 1176-1184.	2.6	18
143	Drug release from extruded solid lipid matrices: Theoretical predictions and independent experiments. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 122-129.	4.3	18
144	Impact of the experimental conditions on drug release from parenteral depot systems: From negligible to significant. International Journal of Pharmaceutics, 2012, 432, 11-22.	5.2	18

#	Article	IF	Citations
145	Quaternary polymethacrylateâ€“magnesium aluminum silicate films: Molecular interactions, mechanical properties and tackiness. International Journal of Pharmaceutics, 2013, 458, 57-64.	5.2	18
146	How agarose gels surrounding PLGA implants limit swelling and slow down drug release. Journal of Controlled Release, 2022, 343, 255-266.	9.9	18
147	Simultaneous controlled vitamin release from multiparticulates: Theory and experiment. International Journal of Pharmaceutics, 2011, 412, 68-76.	5.2	17
148	Accelerated ketoprofen release from polymeric matrices: Importance of the homogeneity/heterogeneity of excipient distribution. International Journal of Pharmaceutics, 2013, 457, 298-307.	5.2	17
149	Carrageenan as an Efficient Drug Release Modifier for Ethylcellulose-Coated Pharmaceutical Dosage Forms. Biomacromolecules, 2007, 8, 3984-3991.	5.4	16
150	Importance of glassy-to-rubbery state transitions in moisture-protective polymer coatings. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 146-153.	4.3	16
151	Cast Lipid Implants for Controlled Drug Delivery: Importance of the Tempering Conditions. Journal of Pharmaceutical Sciences, 2011, 100, 3471-3481.	3.3	16
152	Crystalline Polymorphism Emerging From a Milling-Induced Amorphous Form: The Case of Chlorhexidine Dihydrochloride. Journal of Pharmaceutical Sciences, 2018, 107, 121-126.	3.3	16
153	Characterization of ethylcellulose: starch-based film coatings for colon targeting. Drug Development and Industrial Pharmacy, 2009, 35, 1190-1200.	2.0	15
154	Non-coated multiparticulate matrix systems for colon targeting. Drug Development and Industrial Pharmacy, 2011, 37, 1150-1159.	2.0	15
155	For the special IJP issue â€œPoorly soluble drugsâ€: International Journal of Pharmaceutics, 2013, 453, 1-2.	5.2	15
156	Fenofibrate-loaded PLGA microparticles: Effects on ischemic stroke. European Journal of Pharmaceutical Sciences, 2009, 37, 43-52.	4.0	14
157	Diffusion Controlled Drug Delivery Systems. , 2012, , 127-152.		14
158	PLGAs bearing carboxylated side chains: Novel matrix formers with improved properties for controlled drug delivery. Journal of Controlled Release, 2013, 166, 256-267.	9.9	14
159	In-silico simulations of advanced drug delivery systems: What will the future offer?. International Journal of Pharmaceutics, 2013, 454, 512-516.	5.2	14
160	Analysis of Bulk and Hydration Water During Thermal Lysozyme Denaturation Using Raman Scattering. Food Biophysics, 2013, 8, 170-176.	3.0	14
161	Towards a better understanding of the release mechanisms of caffeine from PLGA microparticles. Journal of Applied Polymer Science, 2020, 137, 48710.	2.6	14
162	Starch-based controlled release matrix tablets: Impact of the type of starch. Journal of Drug Delivery Science and Technology, 2021, 61, 102152.	3.0	14

#	Article	IF	Citations
163	Controlled delivery of a new broad spectrum antibacterial agent against colitis: In vitro and in vivo performance. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 152-161.	4.3	13
164	Controlled release tablets based on HPMC:lactose blends. Journal of Drug Delivery Science and Technology, 2019, 52, 607-617.	3.0	13
165	Injection Molded Capsules for Colon Delivery Combining Time-Controlled and Enzyme-Triggered Approaches. International Journal of Molecular Sciences, 2020, 21, 1917.	4.1	13
166	Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures. International Journal of Pharmaceutics, 2021, 596, 120220.	5.2	13
167	Ethanol-resistant ethylcellulose/guar gum coatings â€“ Importance of formulation parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1250-1258.	4.3	12
168	Fatty acids for controlled release applications: A comparison between prilling and solid lipid extrusion as manufacturing techniques. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 173-184.	4.3	12
169	Importance of air bubbles in the core of coated pellets: Synchrotron X-ray microtomography allows for new insights. Journal of Controlled Release, 2016, 237, 125-137.	9.9	12
170	Coloring of PLGA implants to better understand the underlying drug release mechanisms. International Journal of Pharmaceutics, 2019, 569, 118563.	5.2	12
171	Hybrid Ear Cubes for local controlled dexamethasone delivery to the inner ear. European Journal of Pharmaceutical Sciences, 2019, 126, 23-32.	4.0	12
172	In-situ forming implants for dual controlled release of chlorhexidine and ibuprofen for periodontitis treatment: Microbiological and mechanical key properties. Journal of Drug Delivery Science and Technology, 2020, 60, 101956.	3.0	12
173	Novel insights into controlled drug release from coated pellets by confocal Raman microscopy. Journal of Raman Spectroscopy, 2016, 47, 757-762.	2.5	11
174	How to adjust dexamethasone mobility in silicone matrices: A quantitative treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 100, 27-37.	4.3	11
175	Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use. European Journal of Pharmaceutics and Biopharmaceutics, 2001, 51, 17-24.	4.3	10
176	Enzymatically activated coated multiparticulates containing theophylline for colon targeting. Journal of Drug Delivery Science and Technology, 2010, 20, 193-199.	3.0	10
177	Quaternary polymethacrylateâ€“magnesium aluminum silicate films: Water uptake kinetics and film permeability. International Journal of Pharmaceutics, 2015, 490, 165-172.	5.2	10
178	In-situ forming PLGA implants: How additives affect swelling and drug release. Journal of Drug Delivery Science and Technology, 2019, 53, 101180.	3.0	10
179	PLGA implants for controlled drug release: Impact of the diameter. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 50-60.	4.3	10
180	Mechanisms Controlling Theophylline Release from Ethanol-Resistant Coated Pellets. Pharmaceutical Research, 2014, 31, 731-741.	3.5	9

#	Article	IF	Citations
181	Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis. International Journal of Pharmaceutics, 2017, 533, 26-33.	5.2	9
182	Evaluation of the Efficacy of Dexamethasone-Eluting Electrode Array on the Post-Implant Cochlear Fibrotic Reaction by Three-Dimensional Immunofluorescence Analysis in Mongolian Gerbil Cochlea. Journal of Clinical Medicine, 2021, 10, 3315.	2.4	9
183	Swelling Controlled Drug Delivery Systems. , 2012, , 153-170.		8
184	Preparation of polymeric fenofibrate formulations with accelerated drug release: Solvent evaporation versus co-grinding. Journal of Drug Delivery Science and Technology, 2015, 30, 397-407.	3.0	8
185	Eudragit RL-based film coatings: How to minimize sticking and adjust drug release using MAS. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 126-133.	4.3	8
186	Simulated food effects on drug release from ethylcellulose: PVAâ€“PEG graft copolymer-coated pellets. Drug Development and Industrial Pharmacy, 2010, 36, 173-179.	2.0	7
187	In silico simulation of niacin release from lipid tablets: Theoretical predictions and independent experiments. Journal of Controlled Release, 2014, 175, 63-71.	9.9	7
188	Oral colon delivery platform based on a novel combination approach: Design concept and preliminary evaluation. Journal of Drug Delivery Science and Technology, 2021, 66, 102919.	3.0	7
189	Hot melt extruded PLGA implants loaded with ibuprofen: How heat exposure alters the physical drug state. Journal of Drug Delivery Science and Technology, 2022, 73, 103432.	3.0	7
190	In honor of Takeru Higuchi. International Journal of Pharmaceutics, 2011, 418, 1-2.	5.2	6
191	Robustness of Controlled Release Tablets Based on a Cross-linked Pregelatinized Potato Starch Matrix. AAPS PharmSciTech, 2020, 21, 148.	3.3	6
192	Dexamethasone-loaded cochlear implants: How to provide a desired â€œburst releaseâ€• International Journal of Pharmaceutics: X, 2021, 3, 100088.	1.6	6
193	Progress in film coating. International Journal of Pharmaceutics, 2013, 457, 361.	5.2	5
194	When drugs plasticize film coatings: Unusual formulation effects observed with metoprolol and Eudragit RS. International Journal of Pharmaceutics, 2018, 539, 39-49.	5.2	5
195	Hot melt extruded polysaccharide blends for controlled drug delivery. Journal of Drug Delivery Science and Technology, 2019, 54, 101317.	3.0	5
196	Accelerated ketoprofen release from spray-dried polymeric particles: importance of phase transitions and excipient distribution. Drug Development and Industrial Pharmacy, 2015, 41, 838-850.	2.0	4
197	PEO hot melt extrudates for controlled drug delivery: Importance of the type of drug and loading. Journal of Drug Delivery Science and Technology, 2021, 61, 102238.	3.0	4
198	Injection-molded capsule bodies and caps based on polymer blends for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 168, 1-14.	4.3	4

#	Article	IF	Citations
199	Towards a Better Understanding of Verapamil Release from Kollicoat SR:IR Coated Pellets Using Non-Invasive Analytical Tools. Pharmaceutics, 2021, 13, 1723.	4.5	3
200	Accelerated fenofibrate release from spray-dried microparticles based on polymer blends. Journal of Drug Delivery Science and Technology, 2014, 24, 185-190.	3.0	2
201	Professor Alexander T. Florence: An exceptional scientist and man. International Journal of Pharmaceutics, 2016, 514, 1-2.	5.2	2
202	Poorly soluble drugs. International Journal of Pharmaceutics, 2020, 577, 119055.	5.2	2
203	Microparticles Used as Drug Delivery Systems. , 2006, , 15-21.		2
204	The Modified-Release Drug Delivery Landscape. , 2008, , 17-34.		2
205	Future perspectives in pharmaceutics: contributions from younger scientists. Preface. International Journal of Pharmaceutics, 2008, 364, 157-158.	5.2	1
206	Announcing the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. AAPS PharmSciTech, 2009, 10, 806.	3.3	0
207	Special JDDST issue in honour of Prof. Dominique DuchÃªne. Journal of Drug Delivery Science and Technology, 2015, 30, 251-259.	3.0	0
208	IJPâ€™s Editor for the Americas, Australia and New Zealand. International Journal of Pharmaceutics, 2018, 535, iii.	5.2	0
209	A Warm Welcome to Leena Peltonen as Editor for Europe, Africa and Near East. International Journal of Pharmaceutics, 2020, 587, 119720.	5.2	0
210	Sincere thanks to VÃ©ronique PrÃ©at and Thorsteinn Loftsson and a Warm Welcome to Carmen Alvarez-Lorenzo and Juan Manuel Irache. International Journal of Pharmaceutics, 2020, 576, 119056.	5.2	0
211	Implant cochlÃ©aire et implant auditif central. , 2018, , 115-154.		0
212	Pharmaceutical Technology in Europe. International Journal of Pharmaceutics, 2022, 613, 121441.	5.2	0